Mesenchymal Stem Cells for The Treatment of Frailty Syndrome

Status Recruiting

Clinical Trial Summary

The clinical study with UMC119-06-05 is designed to investigate the safety in patients with frailty syndrome. This will be a dose escalation, open label, single-center study in adult with frailty syndrome. UMC119-06-05 is ex vivo cultured human umbilical cord tissue-derived mesenchymal stem cells product which is intended for treatment of frailty syndrome.

Clinical Trial Description

Frailty syndrome is the most problematic expression of population ageing and profound implications for the planning and delivery of health and social care when population ageing is accelerating rapidly worldwide, from 461 million people older than 65 years in 2004 to an estimated 2 billion people by 2050 . Frailty syndrome characterized by a progressive decline in health and clinical symptoms of exhaustion, weight loss, a feeling of slowing down, and a decrease in functional capacity. Frailty is a common clinical syndrome in older adults that carries an increased risk for poor health outcomes including falls, incident disability, hospitalization, and mortality. Health study as meeting three out of five phenotypic criteria: low grip strength, self-reported exhaustion, slowed walking speed, low physical activity, and unintentional weight loss. Frailty is a disorder of several inter-related physiological systems, including genetic and environmental factors in combination with epigenetic mechanisms, which regulate the differential expression of genes in cells and could be especially important in ageing. Current interventions focus on interdisciplinary approaches which include nutritional supplementation, physical exercise, and cognitive intervention. Clinical studies of these preventative approaches have shown inconsistent and modest benefits, further highlighting the unmet clinical need. Therefore, development of new therapeutic modalities to improve the clinical outcomes and prognosis of frailty syndrome in adult patients is of urgent need. A variety of pharmacologic and biologic therapies are currently being tested to treat aging. Among the more innovative, experimental therapies, Mesenchymal Stromal Cells (MSCs) are represents an attractive option that addresses the pathophysiology of the syndrome. ;

Study Design

Related Conditions & MeSH terms

Clinical Trial Details

NCT number	NCT04914403
Study type	Interventional
Source	Meridigen Biotech Co., Ltd.
Contact	Claire Liao, MS
Phone	+886-2-8978-7777
Email	claire.liao@meridigen.com
Status	Recruiting
Phase	Phase 1
Start date	September 1, 2021
Completion date	July 2025

View Details

See also
Status	Clinical Trial	Phase
Completed	`NCT04888884` - Loss of Independence - a Rapid Alternative to Frailty Screening in a Swedish ED Setting
Active, not recruiting	`NCT05961319` - Smart Home Technologies for Assessing and Monitoring Frailty in Older Adults
Recruiting	`NCT04518423` - Prevalence, Determinants and Natural History of Frailty and Pre-frailty in Elderly People
Active, not recruiting	`NCT04830865` - Adaptation and Validation of Frailty Scales in Intensive Care Units in Spain
Not yet recruiting	`NCT05962203` - SHIP-AGE: Frailty, Renal Function, and Multi-component Primary Care in Rural Mecklenburg-Western Pomerania	N/A
Recruiting	`NCT03963050` - Successful Aging and Frailty	N/A
Recruiting	`NCT04173715` - Movement and Behaviours Measurement Study
Active, not recruiting	`NCT06079762` - AGE SELF CARE: Promoting Healthy Aging Through a Group Visit Program	N/A
Recruiting	`NCT04954690` - Structured Program of Exercise for Recipients of Kidney Transplantation	N/A
Recruiting	`NCT04360109` - Study of the Association Between Presbycusis With the Incidence of Frailty
Recruiting	`NCT04592146` - Maintaining and imPrOving the intrinSIc capaciTy Involving Primary Care and caregiVErs	N/A
Completed	`NCT05668221` - Multidisciplinary Prehabilitation to Improve Frailty and Functional Capacity in High-risk Elective Surgical Patients: a Retrospective Pilot Study
Completed	`NCT03949439` - Pre-frailty and Rehospitalization in Cardiac Surgery
Recruiting	`NCT04746768` - Frailty Syndrome of Post-cancer Treatment Eldery Patients	N/A
Withdrawn	`NCT04321603` - Altering Mechanisms of Frailty in Persons Living With HIV Aged 50 to 65	N/A
Recruiting	`NCT05435534` - Effect of a Multicomponent Intervention on Functional Capacity After Hip Fracture	N/A
Withdrawn	`NCT04241159` - Study to Explore the Safety and Feasibility of Allogeneic Young Plasma Infusion in Older Adults	Early Phase 1
Enrolling by invitation	`NCT02685839` - Development of an Intelligent POWER Rehabilitation Cluster Machine and Its Clinical Testing and Assessment	N/A
Recruiting	`NCT04880824` - Analysis of Frailty Syndrome Within the Framework of the Innovation Fund Project PRÄP-GO (ANA-PRÄP-GO)
Completed	`NCT04877028` - Frailty Screening in the Swedish Emergency Department Setting

Clinical trials are conducted in a series of steps, called phases - each phase is designed to answer a separate research question.

Phase 1: Researchers test a new drug or treatment in a small group of people for the first time to evaluate its safety, determine a safe dosage range, and identify side effects.
Phase 2: The drug or treatment is given to a larger group of people to see if it is effective and to further evaluate its safety.
Phase 3: The drug or treatment is given to large groups of people to confirm its effectiveness, monitor side effects, compare it to commonly used treatments, and collect information that will allow the drug or treatment to be used safely.
Phase 4: Studies are done after the drug or treatment has been marketed to gather information on the drug's effect in various populations and any side effects associated with long-term use.